Takeda awaits PH FDA nod for dengue vaccine Qdenga

Takeda Pharmaceuticals, the maker of the dengue vaccine Qdenga, is awaiting approval from the Philippine Food and Drug Administration (FDA) after submitting all required information.

The company has provided the Philippine FDA with a risk management plan and explanations regarding the vaccine's withdrawal from markets in other countries.

Takeda clarified that the voluntary withdrawal of Qdenga applications in the US and Singapore was due to data collection requirements by their respective health agencies.

The vaccine has already received approval in 40 countries worldwide and has had over 15 million doses distributed globally.

Takeda remains committed to collaborating with global health authorities to ensure Qdenga's thorough evaluation for approval in the Philippines.